Cardium Announces Follow-On Direct Investment by Institutiona...(nal cardiologists as a one-timetreatment...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Cardium Announces Follow-On Direct Investment by Institutional Investor
Date:6/30/2008
nal cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. For more information about Cardium and its businesses, products and therapeutic candidates, please visit http://www.cardiumthx.com or view its 2007 Annual Report at http://www.cardiumthx.com/flash/pdf/CardiumAR07_Book_FINAL.pdf.
Cardium's InnerCool Therapies subsidiary is a San Diego-based medical technology company in the emerging field of patient temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or stroke, and to potentially lessen or prevent associated injuries such as adverse neurological outcomes. For more information about Cardium's InnerCool subsidiary and patient temperature modulation, including InnerCool's Celsius Control System(TM) and the CoolBlue(TM) System, please visit http://www.innercool.com.
Cardium's Tissue Repair Company subsidiary (TRC) is a San Diego-based
biopharmaceutical company focused on the development of growth factor
therapeutics for the treatment of severe chronic diabetic wounds. TRC's
lead product candidate, Excellarate(TM), is a DNA-activated collagen gel
for topical treatment formulated with an adenovector delivery carrier
encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate is
initially being developed to be administered once or twice for the
potential treatment of non-healing diabetic foot ulcers. Other potential
applications for TRC's Gene Activated Matrix(TM) (GAM(TM)) technology
include therapeutic angiogenesis (cardiovascular ischemia, peripheral
arterial disease) and orthopedic products, including hard t
'/>"/>
| SOURCE Cardium Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Cardium Selected for Inclusion in Russell Microcap Index
2. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
3. Cardium Launches New AWARE Clinical Study Website
4. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
5. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
6. Cardium Reports on First Quarter 2008 Highlights and Financial Results
7. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
8. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
9. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
10. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
11. Cardium Completes $5.3 Million Registered Direct Offering
Post Your Comments:
Breaking Biology Technology:Repligen Announces Conference Call to Discuss Phase 3 Clinical Trial Results of RG1068 in MRI Imaging of the Pancreas 2Repligen Announces Conference Call to Discuss Phase 3 Clinical Trial Results of RG1068 in MRI Imaging of the Pancreas 3Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 2Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 3Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 4Reportlinker Adds Pharmacodynamic Assays 2Reportlinker Adds Pharmacodynamic Assays 3Reportlinker Adds Pharmacodynamic Assays 4The Pittsburgh Life Sciences Greenhouse Announces Additions to Nationally Recognized Executive Program 2The Pittsburgh Life Sciences Greenhouse Announces Additions to Nationally Recognized Executive Program 3
[0] Repligen Announces Conference Call to Discuss Phase 3 Clinical Trial Results of RG1068 in MRI Imaging of the Pancreas[0] Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit[0] Reportlinker Adds Pharmacodynamic Assays[0] The Pittsburgh Life Sciences Greenhouse Announces Additions to Nationally Recognized Executive Program
Other Biology Technology:AstraZeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nation's Number One Killer 2AstraZeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nation's Number One Killer 3AstraZeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nation's Number One Killer 4Catalyst Biosciences Expands Scientific Advisory Board With Leading Experts in Protease Therapeutic Discovery and Development 2Catalyst Biosciences Expands Scientific Advisory Board With Leading Experts in Protease Therapeutic Discovery and Development 3Catalyst Biosciences Expands Scientific Advisory Board With Leading Experts in Protease Therapeutic Discovery and Development 4Catalyst Biosciences Expands Scientific Advisory Board With Leading Experts in Protease Therapeutic Discovery and Development 5Catalyst Biosciences Expands Scientific Advisory Board With Leading Experts in Protease Therapeutic Discovery and Development 6
AstraZeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nation's Number One KillerCatalyst Biosciences Expands Scientific Advisory Board With Leading Experts in Protease Therapeutic Discovery and DevelopmentAgendia to Present at BioCentury's Future Leaders in the Biotech Industry Conference
Breaking Biology News(10 mins):Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 2Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 3Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 4Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 5Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 6Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 7Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 8Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 9Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 10First-in-class treatment for acute leukemia 2First-in-class treatment for acute leukemia 3Study finds new relationship between gene duplication and alternative splicing in plants 2Study finds new relationship between gene duplication and alternative splicing in plants 3Blue Belt Technologies Inc Closes Series A Financing 5111 1Blue Belt Technologies Inc Closes Series A Financing 5111 2Blue Belt Technologies Inc Closes Series A Financing 5111 3Abbott Cuts Use of Oil and Coal by 35 Percent 5108 1Abbott Cuts Use of Oil and Coal by 35 Percent 5108 2Abbott Cuts Use of Oil and Coal by 35 Percent 5108 3Urologists Radiologists Patients Benefit From New Clinical Prostate Visualization System 5105 1Urologists Radiologists Patients Benefit From New Clinical Prostate Visualization System 5105 2
Other Biology News:Hybridization partially restores vision in cavefish, NYU study finds 2Scientific evidence supporting evolution continues to grow 2Scientific evidence supporting evolution continues to grow 3American Chemical Society's weekly PressPac -- Jan. 2, 2008 2American Chemical Society's weekly PressPac -- Jan. 2, 2008 3American Chemical Society's weekly PressPac -- Jan. 2, 2008 4American Chemical Society's weekly PressPac -- Jan. 2, 2008 5American Chemical Society's weekly PressPac -- Jan. 2, 2008 6American Chemical Society's weekly PressPac -- Jan. 2, 2008 7American Chemical Society's weekly PressPac -- Jan. 2, 2008 8American Chemical Society's weekly PressPac -- Jan. 2, 2008 9
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |